This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Eurofins Scientific Past Earnings Performance

Past criteria checks 1/6

Eurofins Scientific has been growing earnings at an average annual rate of 18.5%, while the Life Sciences industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 11.4% per year. Eurofins Scientific's return on equity is 6%, and it has net margins of 3.9%.

Key information

18.5%

Earnings growth rate

17.3%

EPS growth rate

Life Sciences Industry Growth	26.8%
Revenue growth rate	11.4%
Return on equity	6.0%
Net Margin	3.9%
Next Earnings Update	24 Jul 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Eurofins Scientific makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

ENXTPA:ERFNV Revenue, expenses and earnings (EUR Millions)
Date	Revenue	Earnings	G+A Expenses
31 Dec 23	6,515	257	136
30 Sep 23	6,512	335	132
30 Jun 23	6,510	414	141
31 Mar 23	6,611	497	141
31 Dec 22	6,712	581	128
30 Sep 22	6,785	612	123
30 Jun 22	6,857	643	117
31 Mar 22	6,787	696	116
31 Dec 21	6,718	749	115
30 Sep 21	6,553	786	117
30 Jun 21	6,388	824	118
31 Mar 21	5,913	665	119
31 Dec 20	5,439	505	119
30 Sep 20	5,079	347	120
30 Jun 20	4,719	190	120
31 Mar 20	4,641	168	119
31 Dec 19	4,563	146	117
30 Sep 19	4,384	144	111
30 Jun 19	4,205	143	106
31 Mar 19	3,993	159	98
31 Dec 18	3,781	175	90
30 Sep 18	3,549	182	82
30 Jun 18	3,318	190	75
31 Mar 18	3,145	185	62
31 Dec 17	2,971	179	48
30 Sep 17	2,848	166	42
30 Jun 17	2,725	152	35
31 Mar 17	2,631	145	37
31 Dec 16	2,537	138	38
30 Sep 16	2,427	104	35
30 Jun 16	2,317	69	32
31 Mar 16	2,133	63	31
31 Dec 15	1,950	56	30
30 Sep 15	1,779	71	27
30 Jun 15	1,609	86	24
31 Mar 15	1,509	82	20
31 Dec 14	1,410	78	15
30 Sep 14	1,355	66	17
30 Jun 14	1,299	53	19
31 Mar 14	1,262	53	15
31 Dec 13	1,226	53	12
30 Sep 13	1,180	61	8

Quality Earnings: ERFNV has a large one-off loss of €189.2M impacting its last 12 months of financial results to 31st December, 2023.

Growing Profit Margin: ERFNV's current net profit margins (3.9%) are lower than last year (8.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ERFNV's earnings have grown by 18.5% per year over the past 5 years.

Accelerating Growth: ERFNV's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: ERFNV had negative earnings growth (-55.8%) over the past year, making it difficult to compare to the Life Sciences industry average (-1.7%).

Return on Equity

High ROE: ERFNV's Return on Equity (6%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/07/03 08:20
End of Day Share Price	2024/07/03 00:00
Earnings	2023/12/31
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Eurofins Scientific SE is covered by 35 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ankush Kathuria	AlphaValue
Pierre-Yves Gauthier	AlphaValue
Hubert D'Aillieres	Banco BPI, S.A.